Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00040105 |
The goal of this clinical research study is to find the highest safe dose of the drugs ZarnestraTM (R115777) and Gleevec (imatinib mesylate) that can be given in combination for the treatment of chronic myelogenous leukemia (CML) in chronic phase. The effect of this combination on the leukemia will also be studied.
Optional Procedures: Participants will be asked to give a small additional amount of blood and bone marrow whenever blood or bone marrow is already being drawn for routine testing. The purpose of this is to investigate the effect of this therapy on the leukemia cells and understand better how the study drugs work together.
Participants will also be asked to have some extra bone marrow samples collected. These samples will be used to analyze RNA. Thousands of different genes will be looked at to see if any of these are affecting the way R115777 works.
Condition | Intervention | Phase |
---|---|---|
Leukemia, Myeloid, Chronic |
Drug: R115777 (Zarnestra) Drug: Imatinib mesylate (Gleevec) |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase I Study of Zarnestra (R115777.USA30) and Gleevec (Imatinib Mesylate) in Chronic Phase Chronic Myelogenous Leukemia (CML) |
Enrollment: | 26 |
Study Start Date: | October 2002 |
Study Completion Date: | March 2009 |
Primary Completion Date: | July 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Zarnestra (R115777)+ Gleevec (Imatinib Mesylate)
|
Drug: R115777 (Zarnestra)
R115777 (400 mg PO Two Times a Day)
Drug: Imatinib mesylate (Gleevec)
Gleevec (400 mg PO Four Times a Day)
|
R115777 is a new drug that blocks the function of an enzyme that is important in making some proteins work. One of the most important targets for this enzyme is a protein that can make cells become cancer. Imatinib mesylate is a drug that blocks the function of the protein that comes from the Philadelphia chromosome. The Philadelphia chromosome is an abnormality in chromosomes 9 and 22 that changes blood cells into leukemia cells.
Before treatment starts, participants will have a physical exam, blood tests (About 3 tubes, 2 teaspoons each), and a bone marrow biopsy. The bone marrow will be removed with a large needle.
Participants in this study will take imatinib mesylate by mouth every day for as long as they stay on study, which means as long as it works.
Participants will also take R115777 twice a day for 2 weeks. This will be repeated every 3 weeks. The amount of each of these medications that participants take will depend on when they enter the study. The doses will be slowly increased from participant to participant until the highest dose that does not cause serious side effects is found.
Participants will be asked to visit their doctor for a physical exam and measurement of vital signs. The frequency of doctor visits will vary depending on physical condition. Blood tests (about 2 teaspoons each) will be done every week during the first 3 weeks of treatment. Blood tests will then be done every 8-12 weeks for the length of the study, as needed. The blood samples will be used for routine lab tests. A bone marrow sample will also be taken to check and measure cells related to the disease every 3 months in the first year and then every 6-12 months. Participants can stay on study for as long as the treatment is considered to be beneficial. Participants will be taken off study if their disease gets worse or intolerable side effects occur.
This is an investigational study. The FDA has authorized the use of imatinib mesylate for patients with CML. It is the combination of imatinib mesylate and R115777 that is experimental. R115777 has been authorized for investigational use only. A maximum of 30 patients will take part in this study. All will be enrolled at M. D. Anderson.
Optional Procedures: Participants who agree will have an additional small amount of bone marrow (about 1 teaspoon) every time they have a bone marrow aspiration. This does not require any additional bone marrow aspiration procedures. A small amount of blood (about 1 teaspoon) will also be collected periodically when scheduled blood samples are collected for routine tests.
Participants who agree will also have two bone marrow aspirates (about 1 teaspoon, total) collected at the start of the study and at the end of Cycle 2.
The RNA sample that is taken from the aspirates will not be stored. Participants who change their mind after giving bone marrow for this study may ask for the samples to be destroyed.
You do not have to agree to take part in the optional procedures in order to receive treatment on this study.
Ages Eligible for Study: | 16 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
M.D. Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Jorge E Cortes, MD | U.T.M.D. Anderson Cancer Center |
Responsible Party: | The University of Texas M. D. Anderson Cancer Center ( Jorge Cortes M.D./Professor ) |
Study ID Numbers: | ID02-169 |
Study First Received: | June 19, 2002 |
Last Updated: | March 20, 2009 |
ClinicalTrials.gov Identifier: | NCT00040105 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Chronic Myelogenous Leukemia, Chronic Phase R115777 Zarnestra Tipifarnib Imatinib Mesylate |
Gleevec Imatinib STI571 NSC-716051 |
Imatinib Leukemia Hematologic Diseases Myeloproliferative Disorders Leukemia, Myelogenous, Chronic, BCR-ABL Positive Chronic Myelogenous Leukemia |
Leukemia, Myeloid, Chronic-Phase Leukemia, Myeloid Bone Marrow Diseases Protein Kinase Inhibitors Tipifarnib |
Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Hematologic Diseases Myeloproliferative Disorders Enzyme Inhibitors Leukemia, Myeloid Leukemia, Myeloid, Chronic-Phase Protein Kinase Inhibitors |
Pharmacologic Actions Imatinib Leukemia Neoplasms Therapeutic Uses Leukemia, Myelogenous, Chronic, BCR-ABL Positive Bone Marrow Diseases Tipifarnib |